相关实验视频

Updated: Jul 4, 2025

Extraction and Analysis of Taiwanese Green Propolis

Extraction and Analysis of Taiwanese Green Propolis

Published on: January 7, 2019

通过超声波获得提取的Apis mellifera的潜在抗糖尿病活性

Javier A Hernández-Martínez¹, Armando Zepeda-Bastida¹, Irma Morales-Rodríguez¹

¹ICAP-Institute of Agricultural Sciences, Autonomous University of the State of Hidalgo, Tulancingo de Bravo 43000, Hidalgo, Mexico.

Foods (Basel, Switzerland)

|January 26, 2024

概括

墨西哥提取物显示出作为糖尿病自然治疗的巨大潜力. 虽然消化减少了抗氧化特性,但它们抑制关键消化酶的能力仍然很强,这表明它们具有治疗价值.

科学领域:

食品化学食品化学
自然产品化学化学
药理学药理学是指药理学的学科.

背景情况:

化合物越来越多地因其消化酶抑制性质而得到认可.
是一种天然树脂混合物,传统上用于各种疾病,并含有各种生物活性化合物.
了解区域的植物化学特征和生物活性对于其治疗应用至关重要.

研究的目的:

量化墨西哥提取物中和黄的总含量.
评估这些提取物的抗氧化剂和消化酶抑制活性 (α-氨基酶,α-葡萄糖酶).
在模拟消化后评估化合物的稳定性和生物活性.

主要方法:

超声波辅助乙醇提取来自墨西哥奥阿哈卡的样品.
在体外测定总 (GAE),总黄 (QE) 和抗氧化能力 (ABTS,DPPH).
对α-氨酶和α-葡萄糖酶进行酶抑制试验,然后进行模拟的体外消化.

主要成果:

来自Eloxochitlán (PE) 的提取物表现出最高的含量 (15,362.4 mg GAE/100 g) 和抗氧化活性 (33,307.1 mg ET/100 g).
来自Teotitlán (PT) 的提取物显示了最高的黄酸含量 (8084.6 mg QE/100 g).
模拟消化显著降低了,黄和抗氧化剂活性 (~96%),但保留了大量的α-氨酶和α-葡萄糖酶抑制作用 (~50%的酶活性减少).

结论:

墨西哥 прополис提取物由于其酶抑制性质,具有显著的抗糖尿病潜力.
虽然消化减少了抗氧化能力,但抗糖尿病作用仍然存在,这表明治疗可行性.
需要进行进一步的研究,以开发将 прополис纳入食品中的保护机制,以保持其有效性.

关键词:

黄类化合物黄类化合物抑制抑制抑制的抑制作用现类是存在于物质中的一种.-氨酸酶是一个 - 葡萄糖化酶

更多相关视频

Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass

Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass

Published on: May 27, 2022

An In Ovo Model for Testing Insulin-mimetic Compounds

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...